We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

R3NK:XETRRENK Group AG Analysis

Data as of 2026-05-18 - not real-time

€44.47

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

RENK Group AG trades at €44.47, well below its 20‑day (€51.17) and 50‑day (€52.44) SMAs and far under the 200‑day SMA of €60.08, signaling a pronounced bearish trend. The RSI of 33 points to oversold conditions, while the MACD histogram remains negative, reinforcing short‑term weakness. Volume is increasing, suggesting accumulation near the technical support at €42.12, but the 30‑day volatility of 45% and a high beta (≈2.1) imply price swings can be abrupt. Fundamentals show a PE of 39 versus an industry average of 29, a PB of 9.2, and a DCF fair value of only €5.30, indicating the stock is markedly overvalued. Despite a modest 4% revenue growth, defense sales are expanding, and the recent Q1 order intake discussion points to capacity upgrades that could benefit medium‑term earnings.
The dividend yield of 1.32% with a 36.8% payout ratio appears sustainable given positive operating cash flow, yet the debt‑to‑equity ratio exceeds 100%, adding balance‑sheet risk. With a market cap of €4.45 bn and a “Strong Buy” consensus from 14 analysts, expectations are high, but the technical picture and valuation gaps warrant caution. Investors should weigh the defensive sector tailwinds against the elevated volatility, overvaluation, and leverage when forming a position.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • RSI in oversold territory
  • Price approaching technical support
  • Increasing volume indicating accumulation

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Defense sector tailwinds and order intake growth
  • Persistently high valuation relative to DCF
  • Elevated volatility and beta

Long Term

> 3 years
Cautious
Model confidence: 5/10

Key Factors

  • Significant overvaluation (PE & PB far above peers)
  • High debt‑to‑equity ratio increasing financial risk
  • Potential for prolonged bearish technical trend

Key Metrics & Analysis

Financial Health

Revenue Growth4.00%
Profit Margin8.35%
P/E Ratio39.0
ROE24.20%
ROA6.36%
Debt/Equity103.93
P/B Ratio9.2
Op. Cash Flow€157.9M
Free Cash Flow€59.0M
Industry P/E29.5

Technical Analysis

TrendBearish
RSI33.2
Support€42.12
Resistance€57.77
MA 20€51.17
MA 50€52.44
MA 200€60.08
MACDBearish
VolumeIncreasing
Fear & Greed Index89.61

Valuation

Fair Value€5.30
Target Price€67.29
Upside/Downside51.31%
GradeOvervalued
TypeBlend
Dividend Yield1.32%

Risk Assessment

Beta0.14
Volatility45.41%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.